Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy

NCT00606528 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT00606528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00606528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy
Lead sponsor
University Health Network, Toronto
Phase
Observational
Overall status
Completed
Start date
February 29, 2008
Completion date
Not reported
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c virus infection